Arvinas, Inc. (ARVN) — SEC Filings
Arvinas, Inc. (ARVN) — 50 SEC filings. Latest: 144 (May 8, 2026). Includes 29 8-K, 7 SC 13G/A, 6 10-Q.
View Arvinas, Inc. on SEC EDGAR
Overview
Arvinas, Inc. (ARVN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: ARVINAS, INC. reported a significant decrease in revenue for the three months ended September 30, 2025, falling to $41.9 million from $102.4 million in the prior year, a 59.1% reduction. However, for the nine months ended September 30, 2025, revenue increased to $253.1 million from $204.2 million, a
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 47 neutral. The dominant filing sentiment for Arvinas, Inc. is neutral.
Filing Type Overview
Arvinas, Inc. (ARVN) has filed 2 144, 29 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 2 SC 13G with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of ARVN's 38 recent filings, 1 were flagged as high-risk, 17 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $41.9M |
| Net Income | $(35.1)M |
| EPS | $(0.48) |
| Debt-to-Equity | 0.05 |
| Cash Position | $787.6M |
| Operating Margin | -104.5% |
| Total Assets | $844.3M |
| Total Debt | $7.6M |
Key Executives
- Dr. Andrew G. von Eschenbach
- Ms. Sarah E. Kelly
- Dr. John G. Martin
- Ms. Lisa A. Bright
- Dr. Heidi L. Feldman
- Dr. Robert T. Small
- Dr. John A. McCluskey
- Dr. Timothy M. Dougherty
- Dr. Lori L. Friedman
Industry Context
Arvinas operates in the highly competitive biotechnology sector, focusing on developing novel protein degrader therapeutics. The industry is characterized by significant R&D investment, long development cycles, and reliance on strategic partnerships for commercialization. Key trends include advancements in targeted therapies, precision medicine, and the increasing importance of platform technologies like Arvinas's PROTACs.
Top Tags
sec-filing (10) · financials (8) · 8-K (7) · 8-k (7) · filing (5) · disclosure (4) · executive-compensation (4) · 10-Q (4) · material-definitive-agreement (4) · governance (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for Q3 2025 | $41.9M | Decreased from $102.4M in Q3 2024, a 59.1% reduction. |
| Revenue for 9 months ended Sep 30, 2025 | $253.1M | Increased from $204.2M in the prior year, a 23.9% rise. |
| Net loss for Q3 2025 | $(35.1)M | Improved from $(49.2)M in Q3 2024. |
| Net loss for 9 months ended Sep 30, 2025 | $(13.4)M | Significantly improved from $(153.8)M in the prior year, a 91.3% reduction. |
| Cash, cash equivalents, and marketable securities | $787.6M | As of September 30, 2025, sufficient to fund operations into H2 2028. |
| Research and development expenses for Q3 2025 | $64.7M | Decreased from $86.9M in Q3 2024, a 25.5% reduction. |
| General and administrative expenses for Q3 2025 | $21.0M | Decreased from $75.8M in Q3 2024, a 72.3% reduction. |
| Research and development expenses for 9 months ended Sep 30, 2025 | $224.1M | Decreased from $264.9M in the prior year, a 15.5% reduction. |
| General and administrative expenses for 9 months ended Sep 30, 2025 | $72.9M | Decreased from $131.3M in the prior year, a 44.5% reduction. |
| Common shares outstanding | 64,224,294 | As of October 31, 2025. |
| Net Loss | $120.4M | Increased from $105.2M in Q2 2024, indicating higher operational costs. |
| Six-Month Net Loss | $235.6M | Increased from $201.3M in the prior year, showing a sustained rise in losses. |
| SEC File Number | 001-38672 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 47-2566120 | Company's tax identification number. |
| Reporting Period | 2025 Q1 | First quarter of fiscal year 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Arvinas, Inc. (ARVN)?
Arvinas, Inc. has 50 recent SEC filings from Feb 2024 to May 2026, including 29 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ARVN filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Arvinas, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Arvinas, Inc. (ARVN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Arvinas, Inc.?
Key financial highlights from Arvinas, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ARVN?
The investment thesis for ARVN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Arvinas, Inc.?
Key executives identified across Arvinas, Inc.'s filings include Dr. Andrew G. von Eschenbach, Ms. Sarah E. Kelly, Dr. John G. Martin, Ms. Lisa A. Bright, Dr. Heidi L. Feldman and 4 others.
What are the main risk factors for Arvinas, Inc. stock?
Of ARVN's 38 assessed filings, 1 were flagged high-risk, 17 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Arvinas, Inc.?
Forward guidance and predictions for Arvinas, Inc. are extracted from SEC filings as they are enriched.